IDEAYA Biosciences, Inc. Diluted Shares Outstanding (Weighted Average)
IDEAYA Biosciences, Inc. (IDYA) reported Diluted Shares Outstanding (Weighted Average) of 92.06 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-04
- IDEAYA Biosciences, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 92.06M shares, a 4.06% increase year-over-year.
- IDEAYA Biosciences, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 88.70M shares, a 0.39% increase year-over-year.
- IDEAYA Biosciences, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 88.58M shares, a 1.38% increase year-over-year.
- IDEAYA Biosciences, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 89.69M shares, a 4.06% increase year-over-year.
- IDEAYA Biosciences, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 88.49M shares, a 8.33% increase from fiscal 2024.
- IDEAYA Biosciences, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 81.68M shares, a 42.00% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 57.52M shares, a 38.79% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. weighted average number of shares outstanding, diluted for fiscal 2022 was 41.44M shares, a 17.57% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 92.06M shares 10-Q · filed 2026-08-04 | 90.39M shares 10-Q · filed 2026-08-04 | 89.78M shares derived: average of 3 quarters · filed 2026-08-04 | 89.76M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 88.70M shares 10-Q · filed 2026-05-05 | 88.64M shares derived: average of 2 quarters · filed 2026-05-05 | 88.99M shares derived: average of 3 quarters · filed 2026-05-05 | 88.86M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | 88.58M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | 89.14M shares derived: average of 2 quarters · filed 2026-02-17 | 88.92M shares derived: average of 3 quarters · filed 2026-08-04 | 88.49M shares 10-K · filed 2026-02-17 |
| 2025-09-30 | 89.69M shares 10-Q · filed 2025-11-04 | 89.08M shares derived: average of 2 quarters · filed 2026-08-04 | 88.45M shares 10-Q · filed 2025-11-04 | 88.48M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | 88.47M shares 10-Q · filed 2026-08-04 | 88.41M shares 10-Q · filed 2026-08-04 | 88.07M shares derived: average of 3 quarters · filed 2026-08-04 | 87.60M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | 88.36M shares 10-Q · filed 2026-05-05 | 87.87M shares derived: average of 2 quarters · filed 2026-05-05 | 87.31M shares derived: average of 3 quarters · filed 2026-05-05 | 84.97M shares derived: average of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | 87.38M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | 86.79M shares derived: average of 2 quarters · filed 2026-02-17 | 83.84M shares derived: average of 3 quarters · filed 2026-02-17 | 81.68M shares 10-K · filed 2026-02-17 |
| 2024-09-30 | 86.19M shares 10-Q · filed 2025-11-04 | 82.08M shares derived: average of 2 quarters · filed 2025-11-04 | 79.78M shares 10-Q · filed 2025-11-04 | 76.15M shares derived: average of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | 77.96M shares 10-Q · filed 2025-08-05 | 76.54M shares 10-Q · filed 2025-08-05 | 72.80M shares derived: average of 3 quarters · filed 2026-02-17 | 69.60M shares derived: average of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | 75.11M shares 10-Q · filed 2025-05-06 | 70.22M shares derived: average of 2 quarters · filed 2026-02-17 | 66.81M shares derived: average of 3 quarters · filed 2026-02-17 | 64.17M shares derived: average of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | 65.33M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | 62.67M shares derived: average of 2 quarters · filed 2026-02-17 | 60.53M shares derived: average of 3 quarters · filed 2026-02-17 | 57.52M shares 10-K · filed 2026-02-17 |
| 2023-09-30 | 60.00M shares 10-Q · filed 2024-11-04 | 58.13M shares derived: average of 2 quarters · filed 2024-11-04 | 54.92M shares 10-Q · filed 2024-11-04 | 53.21M shares derived: average of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | 56.25M shares 10-Q · filed 2024-08-06 | 52.33M shares 10-Q · filed 2024-08-06 | 50.94M shares derived: average of 3 quarters · filed 2025-02-18 | 48.48M shares derived: average of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | 48.37M shares 10-Q · filed 2024-05-07 | 48.29M shares derived: average of 2 quarters · filed 2025-02-18 | 45.90M shares derived: average of 3 quarters · filed 2025-02-18 | 44.09M shares derived: average of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | 48.21M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | 44.66M shares derived: average of 2 quarters · filed 2025-02-18 | 42.66M shares derived: average of 3 quarters · filed 2025-02-18 | 41.44M shares 10-K · filed 2025-02-18 |
| 2022-09-30 | 41.11M shares 10-Q · filed 2023-11-07 | 39.89M shares derived: average of 2 quarters · filed 2023-11-07 | 39.19M shares 10-Q · filed 2023-11-07 | 39.22M shares derived: average of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | 38.66M shares 10-Q · filed 2023-08-10 | 38.63M shares 10-Q · filed 2023-08-10 | 38.60M shares derived: average of 3 quarters · filed 2024-02-20 | 38.39M shares derived: average of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | 38.59M shares 10-Q · filed 2023-05-09 | 38.56M shares derived: average of 2 quarters · filed 2024-02-20 | 38.30M shares derived: average of 3 quarters · filed 2024-02-20 | 36.94M shares derived: average of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | 38.54M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | 38.15M shares derived: average of 2 quarters · filed 2024-02-20 | 36.39M shares derived: average of 3 quarters · filed 2024-02-20 | 35.25M shares 10-K · filed 2024-02-20 |
| 2021-09-30 | 37.77M shares 10-Q · filed 2022-11-08 | 35.31M shares derived: average of 2 quarters · filed 2022-11-08 | 34.16M shares 10-Q · filed 2022-11-08 | |
| 2021-06-30 | 32.85M shares 10-Q · filed 2022-08-15 | 32.32M shares 10-Q · filed 2022-08-15 | ||
| 2020-12-31 | 24.72M shares 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |